Antigenics, Inc.
ANTI
Other OTC0.00
USD
- -
- -
ISIN
US0370311013
CUSIP
037031101
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
-99.75
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Garo Armen
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1850 Terwood Road Huntingdon Valley PA United States of America 19006-5518
- IPO Date
- Aug 24, 2018
- Website
- agenusbio.com
- Similar Companies
- Business
- Antigenics, Inc. (OTC: ANTI), formerly the operating entity of Agenus Inc. (Nasdaq: AGEN) prior to its 2011 name change, operates as a clinical-stage immuno-oncology biotechnology company focused on discovering, developing, and commercializing therapies that harness the immune system against cancer and infectious diseases; headquartered in Lexington, Massachusetts, it was founded in 1994. The company offers core products and services including Retrocyte Display, an antibody expression platform for fully human and humanized monoclonal antibodies; QS-21 Stimulon adjuvant, a saponin-based vaccine enhancer licensed in products like GSK's Shingrix; botensilimab (next-generation CTLA-4 antibody), balstilimab (anti-PD-1 antagonist), zalifrelimab (CTLA-4 antibody), and other checkpoint modulators such as AGEN1181, INCAGN1876 (GITR agonist), INCAGN2390 (TIM-3), INCAGN2385 (LAG-3), MK-4830 (ILT4), and AGEN1884; these target solid tumors including refractory microsatellite stable colorectal cancer (MSS CRC), cervical cancer, pancreatic cancer, melanoma, and urinary tract cancers, with operations spanning the United States, Europe, and international partnerships in regions like greater China, India, and Sri Lanka. Recent major developments within the last two years encompass a $141 million strategic collaboration with Zydus Lifesciences in June 2025, involving $75 million upfront for biologics manufacturing facilities in Emeryville and Berkeley, California, up to $50 million in contingent payments, a $16 million equity investment, and exclusive BOT/BAL rights in India and Sri Lanka; Q3 2025 advancements including French Autorisation d’Accès Compassionnel (AAC) with full reimbursement for BOT/BAL in refractory MSS mCRC, launch of the global Phase 3 BATTMAN trial, and 42% two-year overall survival data in MSS CRC patients; deconsolidation of subsidiary MiNK Therapeutics yielding a $100.9 million gain; strategic realignment announced in late 2024 to cut cash burn to $100 million in 2025, $22 million mortgage financing, and a $10 million bridge from Zydus; plus ongoing partnerships with Incyte, Gilead, Merck, Betta Pharmaceuticals, and UroGen for antibody discovery, cell therapies, and intravesical treatments. Antigenics maintains subsidiaries like SaponiQx for adjuvants and leverages a global clinical footprint with end-to-end cGMP manufacturing, research platforms, and named-patient access programs targeting oncology patients in refractory settings.